Corcept is leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators. In 2012, we received FDA approval of Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advancing the possibilities of cortisol modulation. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. The Oncology MSL role is an exciting opportunity to work at a well-established pharmaceutical company that is poised to have a potential 1st in class oncology product together with a platform extending across multiple therapeutic areas. The initial oncology MSL team will comprise of highly experienced and motivated MSLs that will be focused on thought leader engagement, insight gathering, and scientific education. Territories will be finalized based on the location and experience of hired candidates. The MSL will represent Corcept to the highest ethical and professional standards and in accordance with guidelines, directions, and policies.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Education Level
Ph.D. or professional degree
Number of Employees
251-500 employees